

Adrenocorticotropins. XXXIX. The Solid Phase Synthesis of Methionylglutamylhistidylphenylalanylarginyltryptophylglycine¹

James Blake and Choh Hao Li

Contribution from the Hormone Research Laboratory, School of Medicine, University of California, San Francisco, California 94122.

Received April 19, 1968

Abstract: The heptapeptide, methionylglutamylhistidylphenylalanylarginyltryptophylglycine (I), has been synthesized by the solid phase method. Cleavage of the fully protected peptide from the resin was achieved with hydrogen bromide in trifluoroacetic acid containing 1% mercaptoethanol; the product was completely deblocked with sodium in liquid ammonia to give the biologically active peptide I.

The recent successes in peptide synthesis using the solid phase method²⁻⁴ have led us to investigate this procedure for the synthesis of a peptide related to pituitary hormones. The heptapeptide, methionylglutamylhistidylphenylalanylarginyltryptophylglycine (I), occurs in the structures of melanotropins (MSH),⁵ adrenocorticotropins (ACTH),⁵ and lipotropins (LPH)^{6,7} as shown in Figure 1. It has been synthesized by the classical procedure⁸ and shown to possess melanocyte-stimulating as well as ACTH-releasing activities. Since peptide I contains methionine, glutamic acid, histidine, arginine, and tryptophan, which are known to present problems in peptide synthesis, it was deemed of interest to synthesize I by the solid phase method.

The synthesis of peptide I followed essentially the Merrifield procedure³ with the modifications as indicated in Figure 2. After the first cycle, deblocking was accomplished with the addition of β -mercaptoethanol to the hydrogen chloride-dioxane solution to protect tryptophan from acid oxidation.⁹ The post-coupling treatment with acetic anhydride, as originally suggested by Merrifield,² was used to ensure complete acylation of free amine. The acetylation procedure was shown to consume 97% of free amine in 20 min; therefore, any contaminants that might arise from incomplete coupling (of the BOC amino acids) would be primarily N-acetyl peptides rather than free amine peptides differing from I only by the absence of one amino acid residue. Since N-acetyl peptides should be more readily separable from I (because of charge difference) than free amine peptides, the acetylation procedure should yield a purer product.

Cleavage of the protected heptapeptide from the resin was accomplished with hydrogen bromide in trifluoroacetic acid;³ methyl ethyl sulfide was used as a

scavenger to protect methionine from benzylation^{10,11} and β -mercaptoethanol was used to protect tryptophan from acid oxidation.⁹ The trifluoroacetic acid solution of partially protected heptapeptide was evaporated and submitted to countercurrent distribution in the system *n*-butyl alcohol-acetic acid-water to give two peaks in a ratio of 3:1, with partition coefficient (*K*) equaling 2.2 and 5.8, respectively (Figure 3). The major peak (*K* = 2.2) showed one ninhydrin-positive spot by thin layer chromatography on silica gel; the amino acid analysis¹² of the material recovered from the major peak gave the values Met_{0.90}Glu_{0.89}Phe_{1.08}Arg_{0.95}Gly_{1.00} which are in agreement with the structure of methionylglutamyl-*im*-benzylhistidylphenylalanyl-N^G-tosylarginyltryptophylglycine (II). The yield of II based on starting BOC-Gly-OCH₂⊕ was 30%. Thin layer chromatography of the material in the minor peak (Figure 3; *K* = 5.8) showed one ninhydrin-positive spot corresponding to-peptide II and a stream of ninhydrin-negative, chlorine-positive material with mobility of higher *R_f* value; amino acid analysis showed Met_{0.40}Glu_{0.54}Phe_{0.88}Arg_{1.02}Gly_{1.00}. The amino acid analysis, thin layer chromatography, and behavior in countercurrent distribution (higher *K* than peptide II) are all in agreement with the conclusion that the material in the minor peak is composed of N-acetyl peptides (plus peptide II).

Peptide II was treated with sodium in liquid ammonia¹³ and the product was purified by carboxymethylcellulose chromatography¹⁴ (Figure 4) to give peptide I in a 59% yield (18% over-all yield). Peptide I was shown to be pure by paper electrophoresis and thin layer chromatography on silica gel. Amino acid analysis of an acid hydrolysate and a leucine aminopeptidase digest of peptide I gave Met_{0.90}Glu_{0.99}His_{1.01}Phe_{1.00}Arg_{0.98}Gly_{1.00} and Met_{1.09}Glu_{1.08}His_{0.96}Phe_{1.01}Arg_{0.96}Try_{1.05}Gly_{1.00}, respectively.

MSH assay by the *in vivo* procedure¹⁵ showed that a dose of 1 μ g of peptide I produced a change in

(1) (a) For paper XXXVIII, see J. Blake and C. H. Li, *Biochim. Biophys. Acta*, **147**, 386 (1967). (b) All amino acids occurring in the peptide mentioned in this paper are of the L configuration with the exception of glycine.

(2) R. B. Merrifield, *J. Amer. Chem. Soc.*, **85**, 2149 (1963).

(3) R. B. Merrifield, *Biochemistry*, **3**, 1385 (1964).

(4) A. Marglin and R. B. Merrifield, *J. Amer. Chem. Soc.*, **88**, 5051 (1966).

(5) E. Schröder and K. Lübke, "The Peptides," Vol. II, Academic Press Inc., New York, N. Y., 1966.

(6) C. H. Li, L. Barnafi, M. Chretien, and D. Chung, *Nature*, **208**, 1093 (1965).

(7) M. Chretien and C. H. Li, *Can. J. Biochem.*, **45**, 1163 (1967).

(8) C. H. Li, E. Schnabel, D. Chung, and T. B. Lo, *Nature*, **189**, 143 (1961).

(9) G. R. Marshall, International Symposium on Hormonal Polypeptides, Milan, 1967.

(10) St. Guttman and R. A. Boissonas, *Helv. Chim. Acta*, **42**, 1257 (1959).

(11) R. B. Merrifield *J. Org. Chem.*, **29**, 3100 (1964).

(12) D. H. Spackman, W. H. Stein, and S. Moore, *Anal. Chem.*, **30**, 1190 (1958).

(13) V. duVigneaud and O. K. Behren, *J. Biol. Chem.*, **117**, 27 (1937).

(14) E. A. Peterson and H. A. Sober, *J. Amer. Chem. Soc.*, **78**, 751 (1956).

(15) L. T. Hogben and D. Slome, *Proc. Roy. Soc. (London)*, **B108**, 10 (1931).




Figure 1. Structural comparison of sheep pituitary α -MSH, β -MSH, α -ACTH, β -LPH, and γ -LPH.




Figure 2. Outline of the synthesis of methionylglutamylhistidylphenylalanylarginyltryptophylglycine by the solid phase procedure; BOC-, *t*-butyloxycarbonyl; P, polystyrene-2% divinylbenzene copolymer; Bz, benzyl; Tos, *p*-toluenesulfonyl; DCCI, *N,N'*-dicyclohexylcarbodiimide.




Figure 3. Countercurrent distribution of the partially protected heptapeptide II in the system *n*-butyl alcohol-acetic acid-water (4:1:5 by volume; 5-ml volume of each phase). Distribution was carried out at 24°.

melanophore index in hypophysectomized *Rana pipiens* from 1+ to 3+ within 1 hr.

Experimental Section

BOC-glycyl Resin. To a solution of 4.0 g (22.9 mmol) of BOC-glycine and 3.0 ml (21.6 mmol) of triethylamine in 66 ml of anhydrous ethanol was added 15 g of Bio-beads S-X-2, 200-400 mesh, chloro-




Figure 4. Carboxymethylcellulose chromatography (column, 1.4 × 55 cm) of heptapeptide I. The initial buffer was 0.01 *M* ammonium acetate, pH 4.5. After 50 tubes (4 ml/tube), a gradient with respect to pH and concentration of salt was started by introducing 0.1 *M* ammonium acetate buffer of pH 6.7 through a 500-ml mixing flask containing the starting buffer. Later, the gradient was increased by substituting 0.2 *M* ammonium acetate of pH 6.7 as the solution flowing into the mixing flask.

methylated¹⁶ at 0.72 mequiv/g. The mixture was stirred under reflux for 22 hr and filtered, and the resin was exhaustively washed

(16) Commercially available from Bio-Rad Laboratories, Richmond, Calif.

with ethanol, water, and methanol. A sample of the dried BOC-glycyl resin was hydrolyzed in 1:1 dioxane-constant-boiling HCl, and amino acid analysis showed the glycine content to be 0.31 mmol/g.

BOC-methionyl- γ -benzylglutamyl-*im*-benzylhistidylphenylalanyl-N^G-tosylarginyltryptophylglycyl Resin. A portion of BOC-glycyl resin (1.72 g, 0.53 mmol of glycine) was treated by the following steps: (1) three washings with 10-ml portions of dioxane; (2) cleavage of the BOC group by addition of 8.5 ml of 5.8 *N* HCl-dioxane and shaking for 40 min;¹⁷ (3) three washings with 10-ml portions of dioxane; (4) three washings with 8-ml portions of ethanol; (5) three washings with 8-ml portions of chloroform; (6) neutralization of the hydrochloride with 8 ml of chloroform and 1 ml of triethylamine for 10 min; (7) three washings with 10-ml portions of chloroform; (8) three washings with 10-ml portions of dichloromethane; (9) addition of 2.0 mmol of BOC-amino acid in 6 ml of dichloromethane and shaking for 10 min; (10) addition of 2.1 mmol of *N,N'*-dicyclohexylcarbodiimide¹⁸ in 2 ml of dichloromethane and shaking for 2 hr; (11) three washings with 8-ml portions of dimethylformamide; (12) acetylation by addition of 0.5 ml of acetic anhydride, 0.3 ml of triethylamine, and 8 ml of dimethylformamide, and shaking for 20 min; (13) three washings with 8-ml portions of dimethylformamide; (14) one washing with 8 ml of ethanol; (15) three washings with 8-ml portions of acetic acid; (16) three washings with 8-ml portions of ethanol.

After the first cycle, 0.1 ml of β -mercaptoethanol was added to the HCl-dioxane solution. For BOC-Try-OH, BOC-N^G-Tos-Arg-OH,^{19,20} and BOC-*Im*-Bz-His-OH,²⁰ 5% dimethylformamide-dichloromethane, 10% dimethylformamide-dichloromethane, and 100% dimethylformamide, respectively, were used for solution of the BOC amino acid. For BOC-*im*-Bz-His-OH, 2.5 mmol was used for coupling. After six cycles, the resin was dried under vacuum.

Methionylglutamylhistidylphenylalanylarginyltryptophylglycine

(I). The above protected heptapeptide resin (1.07 g, 0.24 mmol of

(17) After filtration of the dioxane washes, the resin holds *ca.* 5 ml of dioxane which dilutes the added HCl to an effective concentration of 3.65 *N* in the dioxane-resin mixture.

(18) J. C. Sheehan and G. P. Hess, *J. Amer. Chem. Soc.*, **77**, 1067 (1955).

(19) J. Ramachandran and C. H. Li, *J. Org. Chem.*, **27**, 4006 (1962).

(20) E. Schnabel, *Ann.*, **702**, 188 (1967).

peptide) was suspended in 8 ml of trifluoroacetic acid, 1 ml of methyl ethyl sulfide, and 0.1 ml of β -mercaptoethanol. Anhydrous hydrogen bromide was bubbled into this suspension, while shaking, for 30 min. The mixture was filtered, the resin was washed with three 7-ml portions of trifluoroacetic acid, and the combined filtrate was evaporated to a residue which was submitted to countercurrent distribution for 100 transfers in the system consisting of *n*-butyl alcohol-acetic acid-water (4:1:5 by volume). The major peak, *K* = 2.2, tubes 68-84 (Figure 3), was isolated and evaporated to 88 mg (0.073 mmol, 30%) of a glassy residue, methionylglutamyl-*im*-benzylhistidylphenylalanyl-N^G-tosylarginyltryptophylglycine (II). Thin layer chromatography on silica gel (*n*-butyl alcohol-acetic acid-water, 4:1:1) showed one ninhydrin-positive spot at *R_f* 0.4. Amino acid analysis of an acid hydrolysate showed Met_{0.90}Glu_{0.89}Phe_{1.08}Arg_{0.95}Gly_{1.00}.

Peptide II was dissolved in 100 ml of ammonia, freshly distilled from sodium. Small pieces of sodium were added until a permanent blue color remained for 30 min. The solution was evaporated to dryness, and the residue was desalted on IRC-50 resin and eluted with pyridine-acetic acid-water (30:4:66). The lyophilized crude heptapeptide was purified by carboxymethylcellulose chromatography, using ammonium acetate gradient elution, to yield, after three lyophilizations, 42 mg of heptapeptide I (peptide content 98%, 0.043 mmol, 59% yield from peptide II), [α]^{25D} -20° (*c* 0.8, 0.1 *N* acetic acid).

Paper electrophoresis in pyridine acetate buffer (pH 3.7, 400 V, 4 hr) showed one ninhydrin-positive, Pauly-positive spot at a mobility relative to lysine, *R_f* 0.58. Thin layer chromatography on silica gel (*n*-butyl alcohol-acetic acid-water, 4:1:1 by volume) showed one ninhydrin-positive spot at *R_f* 0.1. Amino acid analysis of an acid hydrolysate and leucine aminopeptidase digest (pH 8, 24 hr, 37°) gave Met_{0.90}Glu_{0.99}His_{1.01}Phe_{1.06}Arg_{0.98}Gly_{1.00} and Met_{1.09}Glu_{1.08}His_{0.96}Phe_{1.01}Arg_{0.98}Trp_{1.05}Gly_{1.00}, respectively.

Acknowledgments. We wish to thank J. D. Nelson, D. Gordon and W. F. Hain for their able technical assistance. This work was supported in part by grants from the National Institutes of Health of the U. S. Public Health Service (GM-2907), the Allen Foundation, New York, N. Y., and Mr. Maxwell M. Giffen, New York, N. Y.